Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-1

Contributed by: Business Wire

Tags

Biotechnology
Diabetes
Health
Pharmaceutical
Clinical Trials
Diabetology Limited

More Like This

Over 55,000 people already on Simple Online Healthcare's waitlist for UK's first, newly approved oral GLP-1

PR Newswire associated0

Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy® in a pill*) at ObesityWeek® 2025, including demonstrated reductions in cardiovascular risk factors

ProLynx announces preclinical results of long-acting semaglutide requiring once monthly dosing

First GLP-1 tablet for weight loss approved in the UK

First Participant Dosed in First-in-Human Phase 1 Study of GZC8072, a Novel Ultra-Long-Acting Once-Weekly Oral Peptide GLP-1 RA

PR Newswire associated0

Wegovy® pill demonstrated greater weight loss than orforglipron and lower odds of stopping medication due to side effects in a new indirect comparison to be presented at Obesity Medicine Association 2026

PR Newswire associated0

Novo Nordisk to present new data in oral semaglutide 25 mg (Wegovy® in a pill*) and obesity pipeline at ObesityWeek® 2025

PR Newswire associated0

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association's 85th Scientific Sessions